Nalaganje...
Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment
OBJECTIVE: Imatinib has been investigated for the treatment of systemic sclerosis (SSc) because of its ability to inhibit the platelet-derived growth factor receptor and transforming growth factor-β signaling pathways, which have been implicated in SSc pathogenesis. In a 12-month open-label clinical...
Shranjeno v:
| izdano v: | J Rheumatol |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5860882/ https://ncbi.nlm.nih.gov/pubmed/28298564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3899/jrheum.160833 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|